Source: http://docplayer.net/3791913-Cord-blood-banking-and-biologic-license-application-bla-november-19-2010.html
Timestamp: 2018-06-18 08:40:25
Document Index: 74996971

Matched Legal Cases: ['arts 201', 'art 202', 'arts 210', 'art 600', 'art 610', 'art 1271', 'arts 1']

Cord Blood Banking and Biologic License Application (BLA) November 19, PDF
Download "Cord Blood Banking and Biologic License Application (BLA) November 19, 2010"
1 Cord Blood Banking and Biologic License Application (BLA) November 19,
2 Webinar Presenters Tara Sadeghi, BS University of Texas MD Anderson Cord Blood Bank Michele Carbone, MS, CLS, MT(ASCP)SH,DLM,CQM, CQA,CQPA,BQS,RA San Diego Blood Bank, Cord Bank and Stem Cell Therapy Center In accordance with the standards of the Accreditation Council for Continuing Medical Education (ACCME), all speakers are asked to disclose any real or apparent conflicts of interest, which may have a direct bearing on the subject matter they will be presenting. These speakers have indicated no conflict of interest to disclose. This information was disclosed in written form in compliance with the ACCME Standards for Commercial Support of Continuing Medical Education. 2
3 CORD BLOOD BANKING BIOLOGICS LICENSE APPLICATION Tara Sadeghi, BS Michele Carbone MS, CLS, MT(ASCP) 3
4 Objectives Review of the regulations to include 1271 NMDP IND Validation Plan to the FDA and a pre- BLA meeting prior to BLA submission BLA 356h Form Details based on standards to meet the BLA requirements 4
5 REVIEW OF THE REGULATIONS 5
6 Cord blood from unrelated donors is a biologic drug product FDA regulations for cord blood apply to CB units manufactured in the U.S. or distributed to the U.S. Relevant regulations are many Listed at the end of this presentation Two guidance documents released in October 2009 Final guidance regarding licensure Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications (HPC-C Licensure Guidance) - 10/20/09 rmation/guidances/blood/ucm pdf Draft guidance regarding investigational new drugs Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications (Draft HPC-C IND Guidance) 10/20/09 rmation/guidances/blood/ucm pdf
7 Time Line With publication of these HPC-C guidance documents, FDA announce that phase-in implementation for IND and BLA requirements will end 10/20/11 Sponsors are encouraged to send in IND and BLA applications as soon as possible to allow sufficient time for review, comment, and resubmission as needed to complete all actions Does not actually have to be approved by this time Expected that all units distributed after October 2011 be under BLA or IND For non-u.s. banks, only applies to those units coming to the U.S.
8 Scope of the Guidance Documents Placental/umbilical CB units that are: Minimally manipulated Intended for hematopoietic reconstitution in patients with a specified list of diseases Intended for unrelated use
9 Applicable Diseases and Conditions Hematological malignancies Certain lysosomal storage and peroxisomal enzyme deficiency disorders Hurler Syndrome Krabbe Disease X-linked Adrenoleukodystropy Primary immunodeficiency diseases Bone marrow failure Beta thalassemia
10 Biologics License Application (BLA) Guidance for Industry: Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications How the guidance helps: FDA intends to grant a license for CB units shown to follow recommendations in the guidance and meet applicable regulatory requirements License would apply to all HPC-Cs manufactured after approval of license and those previously manufactured that are demonstrated to be comparable Guidance explains: Scope (products covered), historical background, lists and explains the applicable regulatory requirements License application procedure Form FDA 356h, information to include, and actions that FDA will take
11 Information in the HPC-C Licensure Guidance CMC Table summarizes characteristics of the cord blood used to obtain the clinical data submitted to the docket to demonstrate safety, purity, and potency of HPC-C; applicant expected to obtain similar results if citing docket Manufacturing information to be submitted SOPs Processing validation data Control of aseptic manipulations Test methods and validation
12 Special Issues for BLAs Banks are not required to follow recommendations in guidance, but must still submit a BLA Units already stored can be used as long as: HPC-C manufactured using the same procedures where documentation is provided: Demonstrating their comparability, and that they were manufactured in accordance with CGMP HPC-C in inventory that were previously manufactured using different procedures, provided that: Manufacturer submits a separate validation summary, and Includes data demonstrating comparability of previously manufactured HPC-C to the currently manufactured HPC-C, and providing evidence that methods, facilities, and controls used for manufacture conformed to CGMP
13 Establishment Description Guidance on the content and format of information to be submitted in this section of the BLA Floor diagram, personnel and product flow, HVAC, facility controls, computer systems Contamination/cross-contamination issues including equipment cleaning and validation; containment features
14 Investigational New Drugs Application Draft Guidance for Industry and FDA Staff: Investigational New Drug Applications (INDs) for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications Intended for unlicensed CB units that are a suitable match for recipients with serious or life-threatening disease for which there is no satisfactory alternative treatment
15 Applicable Scenarios for Cord Blood INDs Manufactured in non-u.s. banks, listed in international registries, and selected for U.S. patient Manufactured in U.S. banks before BLA has been approved and not shown to meet licensing criteria Prospectively manufactured in U.S. banks and do not meet licensing criteria but for which there is no satisfactory alternative
16 Non-U.S. Cord Blood Banks Non-U.S. banks may choose not to apply for licensure If so, must export CB units to U.S. under an IND Products from non-u.s. banks will often not meet the criteria for licensure, for example: Donor eligibility determination Release criteria
17 U.S. Cord Blood Banks Pre-licensure Inventory For CB units that cannot be shown to be comparable to licensed CB units Needed for treatment of patients with the diseases or conditions applicable to the guidance
18 U.S. Cord Blood Banks Prospectively Manufactured CB Units Not Meeting Licensure Requirements CB units for under-represented populations Intended to maintain diversity of HLA phenotypes of units in inventory
19 Minimal Information to Include in IND Outlined in Table A of Draft Guidance Column A: Non-U.S. Cord Blood Banks Column B: Pre-licensure inventory Column C: Prospectively manufactured unlicensed inventory
20 IND Responsibilities INDs can be submitted by: Cord Blood Banks Registries Sponsor/Investigators Responsibilities for maintaining the IND are listed in part IV of the guidance Communication with the FDA Center for Biological Evaluation and Research is encouraged prior to submission of IND
21 Back to Options for Non-U.S. Banks Submit a BLA or IND to the FDA Advantage: All units are permitted to enter U.S. regardless of whether or not they are through an IND-holding registry Disadvantage: Arduous process requiring demonstration that ALL units meet licensure or IND requirements even if not distributed to the U.S.
22 Back to Options for Non-U.S. Banks Distribute CB units to U.S. exclusively through a registry, affiliated U.S. establishment, or clinical program that holds an IND Advantage: Primary responsibilities for submitting and maintaining IND fall on registry, affiliate, and/or clinical program Do not have to meet stringent requirements for all CB units Disadvantage: Can only distribute units to U.S. if found via an IND-holding registry or by an IND-holding clinical program
23 National Marrow Donor Program Plans to submit an IND for CB units from non-u.s. banks Sponsor would be NMDP and investigators would be U.S. transplant physicians Non-U.S. bank responsibilities would include: Registration with FDA Qualification process by NMDP (prefers accreditation by FACT-NetCord or AABB, may be alternatives) Report adverse events to NMDP and participate in investigations Comply with NMDP procedures for establishing donor eligibility, etc. Some unknowns and challenges related to cost recovery and oversight
24 How FACT-NetCord Accreditation Helps Potential qualification criterion for registry INDs, such as NMDP Requirements for INDs and/or licensures are already required in the Cord Blood Standards Peer-reviewed inspections verify compliance to Standards requirements
25 Applicable U.S. FDA Regulations 21 CFR Parts 201, and 610 Subparg G Labeling 21 CFR Part 202 Prescription Drug Advertising 21 CFR Parts 210 and 211 cgmps 21 CFR Part 600 Biological Products: General 21 CFR Part 610 General Biological Products Standards 21 CFR Part 1271
26 Selected Guidances Useful for INDs Guidance for FDA Reviewers and Sponsors: Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs) Draft Guidance for Industry: Validation of Growth-Based Rapid Microbiological Methods for Sterility Testing of Cellular and Gene therapy Product. Draft Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products Guidance for Industry CGMP for Phase 1 Investigational Drugs
27 NMDP INVESTIGATIONAL NEW DRUG (IND) 27
28 Investigational New Drug (IND) Based on the Guidance Document IND Biologic License Application ( BLA) Compliance with the regulations Licensed product Defined the intended use NMDP Off label use Manufacture cord blood units that do not meet the regulations and guidance standards and BLA requirements NMDP and changes 28
29 VALIDATION PLAN AND THE PRE- BLA MEETING 29
30 Validation Plan / Pre- BLA Meeting Establish and Maintain Define, document and implement and review and as needed revise on an on-going basis Quality Plan (Quality Program) Designed to prevent, detect and correct deficiencies that may lead to circumstances that increase the risk of introduction, transmission or spread of communicable diseases Level 2 documents Level 3 documents 30
31 Validation Plan / Pre- BLA Meeting Level 2 Documents (Quality Management Systems) Personnel SOP on SOP Equipment ( Qualification) Training and Competency Supplier Qualification/ Supply Qualification Validation ( Assay, Process) Labeling Transport Good Documentation Practices Environmental Monitoring Occurrence Reporting Audit 31
32 Validation Plan / Pre- BLA Meeting Quality Systems Audit SOP Document Control Equipment Occurrence Management Record Management Facilities and Environment Cord Blood Personnel Training Competency Validation Supplier and Supply Qualification Labeling 32
33 Quality Management Tools Standard Operating Procedures Quality Management Plan Supporting Documents 33
34 Validation Plan / Pre- BLA Meeting Level 2 Documents Personnel Education, training, experience to enable that person to perform the assigned functions- qualified with GMP Supervising capacity Perform their functions in such a manner to provide assurance that the product has the safety, identity, quality, purity, and potency Quality Unit Labeling Product Insert Distinct Identification Code - DIN ISBT- register with ICCBBA Labeling requirements for donor eligibility (biohazard and warning labels) Base label ISBT requirements 34
35 Validation Plan / Pre- BLA Meeting Level 2 Documents Labeling Base label Proper name of the product Name, address and license number Lot number or other lot identification use the DIN number (So anything that is prepared from that lot number is considered same lot number) Expiration date Preservative Amount of product Rx Partial label Proper name Lot number or other lot identification (DIN) Name of manufacturer- name and address 35
36 Validation Plan / Pre- BLA Meeting Level 2 Documents Equipment Evaluate based on manufacturing need and intended use Qualified Cleaned and maintained Manufacturer recommendation- PM, Calibration Identified within the production records Records and documentation Validation Key Elements Assay» Plan Process» Approval» Acceptance criteria 36
37 Validation Plan / Pre- BLA Meeting Level Documents Assay validation- Level II document Each individual validation and procedure is your level III document Sterility IDM Hemoglobin Safety CBC ( Cord sample) CD34 Viability Potency/Purity ABO HLA CFU Identity 37
38 Validation Plan / Pre- BLA Meeting Level 2 Documents Assay validation plan with acceptable criteria and meet the compendium requirements as defined in the guidance documents Requirements Accuracy Precision Linearity or Reportable range Sensitivity Limit of detection (LOD) 38
39 Validation Plan / Pre- BLA Meeting Level 2 Documents Occurrence Management System Adverse Event - biologics - form 3500A Outcomes that are both serious and unexpected that result in outcomes Death Life threatening adverse experience Prolongation of existing hospitalization Biologic Product Deviation ( report) - form 3486 Product deviations form cgmp, applicable standards or established specifications that may affect the safety, purity and potency Of a distributed product Testing, processing, packaging, labeling, storage or distribution FDA inspection during that process and if they find something they track to the BPDR 39
40 Validation Plan / Pre- BLA Meeting Level 2 Documents Environmental monitoring What is required Biological Safety Cabinet vs Clean room Cleaning supplies used Bioburden Use both a dynamic and a static for the initial validation Monitor on a regular basis Contamination» Take the equipment out of use and clean» Re-assess for bioburden levels» Acceptable limit of less than 3 CFU - SOP is provided 40
41 VALIDATION PLAN AND THE PRE- BLA MEETING 41
42 Validation Plan / Pre- BLA Meeting Audit Outcomes Quality Indicators Collection Transport Testing Stability Thawing Cord Blood Recruiting Eligibility Processing Environment Distribution Supplies 42
43 Validation Plan / Pre- BLA Meeting Validation plan and on your way to the BLA Guidance lists what you need to validate Cord Blood Collection Sterile Viable» Determine your time frame for processing to retain the viability Average and range for your volume and TNC» Determine your time frame for processing to retain the viability Cord Blood Processing Sterile Viable Recovery TNC and CD34 HCT 43
44 Validation Plan / Pre- BLA Meeting Validation plan and your way to the BLA Guidance lists what you need to validate Storage- holding the HCT/P for future processing and/or distribution Actual storage of the cord blood unit and the continuous monitoring of that storage environment» From the time of collection to transport to laboratory» Storage at collection site/ laboratory before and during processing» Storage in the LN2 vapor or actual liquid» Vapor storage - the validation should include the length of time before the cords are exposed to warmer temperatures» Include the overwrap process component 44
45 Validation Plan / Pre- BLA Meeting Validation plan and your way to the BLA Guidance lists what you need to validate Shipping Temperature maintained within the shipper Tracking Thawing- need to establish a acceptable range Viability Recovery percentage 45
46 Validation Plan / Pre- BLA Meeting Validation plan and on your way to the BLA Guidance lists the required SOP Flow diagram that outlines each process starting with recruitment and the corresponding SOPs as listed in the guidance document Collection» Maternal screening» Donor eligibility Physical Screening MRQ MHQ Infectious Disease Testing Additional Medical Chart Review Post donation information Donor Eligibility Screening and Testing 46
47 Validation Plan / Pre- BLA Meeting Validation plan and your way to the BLA Guidance lists the required SOP Flow diagram that outlines each process starting with recruitment and the corresponding SOPs as listed in the guidance document Collection» Maternal screening» Donor eligibility» Notification of moms» Positive Identification or a way of linking the patient demographics with the DIN number» Collection» Storage» Transport back to the processing laboratory 47
48 Validation Plan / Pre- BLA Meeting Validation plan and your way to the BLA Guidance lists the required SOP Flow diagram that outlines each process starting with recruitment and the corresponding SOPs as listed in the guidance document Processing» Manufacturing process» Storage» Lot release Selection» Registry listing Shipping and Handling» Shipping» Thawing» Emergency product 48
49 BLA Form FDA 356h BLA 4-page document with instructions attached» 49
50 BLA Form FDA 356h 50
51 BLA Form FDA 356h 51
52 Biologics License Application- pg 1 APPLICATION INFORMATION PRODUCT DESCRIPTION Established name Hematopoietic Progenitor Cells, Cord HPC-C Indications for use Intended for hematological reconstitution in patients with defined diseases as listed and in the summary APPLICATION DESCRIPTION Application type BLA Type of Submission Original application REASON FOR SUBMISSION New application for biologic license PROPOSED MARKETING STATUS PRESCRIPTION PRODUCT ( RX) ESTABLISHMENT INFORMATION Locations Ready for Inspection CROSS REFERENCES IND- ( NMDP) 52
53 Biologics License Application- pg 2 Page 2 Application contains Index Summary Chemistry Section A. Chemistry, manufacturing and control information C. Methods validation package Certification 53
54 Biologics License Application- BLA Cover letter Introduce the bank and your product Index ( #1 on page 2 of the BLA) Index outlining what is in the submission package Draft label Summary ( #3 on page 2 of the BLA) Summary of the information submitted in the application Product and application description 54
55 Biologics License Application- BLA Index Cover letter Draft label Form FDA356h- Summary Chemistry, Manufacturing and Controls (CMC) Validation Summary Data Facility Description Other 55
56 Biologics License Application- BLA Summary section In enough detail that the reader may gain a good understanding of the data and information Discuss all aspects of the application Synthesize the information into a well- structured and unified document Data should be submitted in a tabular or graphic form 56
57 Biologics License Application- BLA CMC section A. HPC-C Description and Characteristics Table on page 9 of the Guidance document Describe the test and the expected results for your product specifications B. Manufacturer (s) 1. Identification list Name and address All licenses / registration ( CLIA, FDA)» Manufacturer ( Cord Blood Bank)» All collection sites» Laboratory performing testing 57
58 Biologics License Application- BLA CMC section B. Manufacturer 1. Identification of all Manufacturer (s) 2. Floor diagram a) Narrative Description 3. Contamination procedure a) Aseptic technique b) Help to identify or prevent 58
59 Biologics License Application- BLA CMC section C. Methods of Manufacturing 1. SOPS 2. Validation 3. Flow Charts 1. Visual representation 2. List your in- process controls 3. Test performed at each step 4. Time limits 4. Microbiology Use pre- sterilized one time use than you just need to describe it Sterilize in house than you will need to submit validation 5. Control of Aseptic 1. Describe your bioburden monitoring and sterility testing 59
60 Biologics License Application- BLA CMC section D. Container Closure System Describe your bag Describe the over wrap E. Method Validation 1. IDM a) List all the tests, manufacturer, IVD status 2. Other Test Methods a) Describe your test methods for all the tests performed for the safety, purity, potency and identity 60
61 Biologics License Application- BLA CMC section F. Labeling Include your labels G. Environment Assessment Based on the regulation- it is a categorical exclusion 61
62 Thank you for joining us today. Join us for the upcoming inspection and accreditation workshops: Cellular Therapy February 16, 2011 in Honolulu, Hawaii at BMT Tandem Meetings May 18, 2011 in Rotterdam, the Netherlands at ISCT Annual Meeting Cellular Therapy Collection May 31, 2011 in Scottsdale, Arizona at ASFA Annual Meeting Cord Blood June 12, 2011 in San Francisco, CA 62
63 Evaluations and Continuing Education Credit Continuing education credits can be purchased via the online FACT store at All inspectors can obtain CME/CNE certificates free of charge Program and bank personnel requesting CME/CNE credit can purchase credit for 20 USD Evaluations will be distributed to participants not wishing to receive CME/CNE credit 63
64 QUESTION AND ANSWER SESSION 64
TABLE OF CONTENTS EXECUTIVE SUMMARY... 3 GENERAL INFORMATION... 6 BACKGROUND/HISTORY... 7 FACILITY DESCRIPTION: FLOOR DIAGRAMS...
MEMORANDUM BLA 125397 CMC Review of Original Submission Hematopoietic Progenitor Cells- Cord Blood (HPC-C) HEMACORD TM National Cord Blood Program (NCBP) of New York Blood Center (NYBC) Reviewed by: Division
MEMORANDUM. BLA 125407 CMC Review of Original Submission HPC, Cord Blood. Duke University of School of Medicine, Carolina Cord Blood Bank
MEMORANDUM BLA 125407 CMC Review of Original Submission HPC, Cord Blood Duke University of School of Medicine, Carolina Cord Blood Bank Division of Cellular and Gene Therapies Office of Cellular, Tissue,
Share the Science FDA Licensure of HPC, Cord Blood: How Licensure Has Improved Cord Blood Banking
Share the Science FDA Licensure of HPC, Cord Blood: How Licensure Has Improved Cord Blood Banking Presented by: Sharon Miller, MT(ASCP), CHS(ABHI) University of Colorado Cord Blood Bank Director of Regulatory